Key Takeaways
- Opportunity is diagnosed, eligible and reachable patients—not prevalence.
- Assess who controls adoption across specialists, institutions, payers and support channels.
- Evaluate the competitive market at launch, not only today’s market.
- Feasibility of commercialization is part of opportunity—not separate from it.
Emerging biotechnology companies and investors often need a clearer answer to a basic question: how large is the real commercial opportunity?
Forecast precision can create false confidence. The stronger discipline is pressure-testing the assumptions underneath the forecast. That is the purpose of commercial due diligence and related opportunity assessment.
Start With Patients
Examine prevalence, diagnosis rates, eligibility criteria, treatment rates, geography and care settings. Ask what prevents treatment today. Related framework: commercial due diligence framework.
Understand Adoption Control
Prescribers are not always the only decision makers. Institutions, referral networks, payers, specialty pharmacy and patient services can determine whether a clinical decision becomes a treated patient.
Competition and Access at Launch
Assess the future competitive landscape and the practical access journey. Coverage without executable pathways is not commercial success. See market access planning before FDA approval.
Include Commercialization Feasibility
An attractive market that requires capabilities the company cannot build or fund on the intended timeline is a different opportunity than the spreadsheet implies.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
